Details of the Drug

General Information of Drug (ID: DMF4I1V)

Drug Name

FT-0710230

Synonyms

Meconic acid; Mekonsaure; NSC 805; NSC-805; NSC805; Opium acid; Poppy acid; Q421116; SCHEMBL546968; SCHEMBL600257; UNII-V502I79516; V502I79516; ZEGRKMXCOCRTCS-UHFFFAOYSA-N; ZINC1587602; Opio; Papaver somniferum exudate; Papaver somniferum resin; 3-HYDROXY-4-OXO-4H-PYRAN-2,6-DICARBOXYLIC ACID; 3-Hydroxy-4-oxo-1,4-pyran-2,6-dicarboxylic acid; 3-Hydroxy-4-oxopyran-2,6-dicarboxylic acid; 3-hydroxy-4-oxo-pyran-2,6-dicarboxylic acid; 3-hydroxy-4-pyrone-2,6-dicarboxylic acid; 497-59-6; 4H-Pyran-2, 3-hydroxy-4-oxo-; 4H-Pyran-2,6-dicarboxylic acid, 3-hydroxy-4-oxo-; 4H-Pyran-2,6-dicarboxylicacid, 3-hydroxy-4-oxo-; BDBM50147502; C20209; CHEMBL109516; CTK1D7773; DB-083476; DTXSID2060096; EINECS 207-848-2

Indication

Disease Entry	ICD 11	Status	REF
Opioid dependence	6C43.2Z	Phase 3	[1]

Structure

3D MOL

2D MOL

Cross-matching ID

PubChem CID: 10347
INTEDE ID: DR1203

Molecular Interaction Atlas of This Drug

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT02502175) Comparing Opium Tincture (OT) With Methadone for Medication-assisted Treatment of Opioid Use Disorder.
2	Interpretation of opiate urine drug screens.
3	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
4	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
5	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
6	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
7	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
8	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
9	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
10	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
11	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
12	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.